Purchase Order 75N91019P00367

<p>The National Cancer Institute awarded a purchase order to Dhhs State Public Health Lab for $5,000.00 in laboratory and testing services on August 28, 2017, with final completion scheduled for December 17, 2018. Work is performed in Rockville, Maryland under firm fixed price terms with no small business set-aside. The awardee is a North Carolina state government entity operating as a federal prime contractor.</p>

<p>The National Cancer Institute, a civilian federal agency, awarded a firm-fixed-price purchase order contract worth $14,500.00 to Labcorp Genetics Inc. for genetic testing services. The contract has an ultimate completion date of October 31, 2025 and was awarded on April 30, 2025. This contract award is not associated with a larger contract vehicle and does not have a set-aside designation.</p>

This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI) to Labcorp Early Development Laboratories Inc., a subsidiary of Laboratory Corporation of America Holdings, to provide laboratory testing and quality assurance services for the LMB-100 drug product. The objective is to conduct the required testing and assays to support the Investigational New Drug (IND) application for LMB-100, an anti-mesothelin immunotoxin being developed by NCI's Laboratory of Molecular...

<p>The National Cancer Institute issued a purchase order to Adaptive Biotechnologies Corporation on April 29, 2019, for lab testing services valued at $15,062.50, with ultimate completion on May 29, 2019. Performance takes place in Seattle, Washington. The order procures laboratory testing services on a firm fixed-price basis without set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $10,212.50 on August 12, 2019, for lab testing services. Performance concludes September 11, 2019, with work performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Global Life Sciences Solutions USA LLC for $24,441.58 on April 24, 2018, to supply laboratory supplies. The order carries no small business set-aside. Performance occurs in Marlborough, Massachusetts. Ultimate completion is May 23, 2018. The contract uses firm fixed price terms.</p>

<p>The National Cancer Institute awarded a purchase order to Promega Corporation on September 17, 2020, valued at $14,117.40 for scientific equipment. Performance occurs in Madison, Wisconsin, with an ultimate completion date of October 31, 2020. The order is priced firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $24,998.51 in scientific laboratory equipment on March 11, 2021, with an ultimate completion date of May 31, 2021. Performance takes place in Marshallton, Delaware. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Interpflow Corporation for $14,875.00 on August 6, 2019, for laboratory testing. Work is performed at Bethesda, Maryland, with an ultimate completion date of August 31, 2019. The contract is priced as firm fixed price with no set-aside used.</p>

<p>The National Cancer Institute awarded a purchase order to Colorado Department of Public Health &amp; Environment for $10,000.00 on August 28, 2017, for laboratory and testing services. Work is performed in Rockville, Maryland. The order carried a firm fixed price and ultimate completion date of September 18, 2018. No set-aside was used.</p>